Complement Requirement of the Neutralizing Antibody Appearing After Immunization with Smallpox Vaccine
スポンサーリンク
概要
著者
-
Takeuchi Yoshinao
Department Of Pediatrics Kawasaki Municipal Hospital
-
Nishimura Chiaki
Department Of Medical Informatics School Of Medicine Faculty Of Medicine Toho University
-
Kimura Mikio
Department of Chemistry, Faculty of Science and Engineering, Saga University
-
KIMURA Mikio
Department of Virology and Rickettsiology, The National Institute of Health
-
NOMURA Masako
Department of Virology and Rickettsiology, The National Institute of Health
-
KITAOKA Masami
Department of Virology and Rickettsiology, The National Institute of Health
関連論文
- Japanese Clinical Trials with Takeda Acellular Pertussis Vaccine(I. Current Situation of Acellular Pertussis Vaccines)(Clinical Aspects of Acellular Pertussis Vaccines)
- A Trial of Alloreactive T-cell Depletion Using Biotinylated Galactose Oxidase for the Prevention of Acute Graft-versus-Host Diseases
- Trial of Isolation of a Virus from Sera of Patients with Kawasaki Disease
- Polyclonal Increases of Serum Immunoglobulins and Increase of Immunoglobulin-Bearing Peripheral Blood Lymphocytes in Children with Kawasaki Disease
- Bone Marrow Transplantation in Children
- Serologically silent hepatitis B virus infection in infants
- Usefulness of a New DNA Diagnostic Method for Malaria; Microtiter Plate-Hybridization(Abstracts from the Malaria Workshop)
- CASES OF OVALE MALARIA AND MALARIAE MALARIA SUCCESSFULLY TREATED WITH MEFLOQUINE
- Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin
- Aerosol Infection Test for Evaluation of Pertussis Vaccine(I. Current Situation of Acellular Pertussis Vaccines)(Clinical Aspects of Acellular Pertussis Vaccines)
- Characterization and Clinical Study on the Acellular Pertussis Vaccine Produced by a Combination of Column Purified Pertussis Toxin and Filamentous Hemagglutinin(I. Current Situation of Acellular Pertussis Vaccines)(Clinical Aspects of Acellular Pertussis
- Pertussis Vaccine Acceptance Rates and Incidence of Pertussis in Forty Seven Districts (Prefectures) in Japan Since 1977(I. Current Situation of Acellular Pertussis Vaccines)(Clinical Aspects of Acellular Pertussis Vaccines)
- Evaluation of Mumps Antibodies after Measles-Mumps-Rubella (MMR) Vaccines
- Correlation of the Modified Scratch Test with the Radioallergosorbent Test (RAST) in Atopic Children
- Effects and Side Effects of a New Trivalent Combined Measles-Mumps-Rubella (MMR) Vaccine
- Clinical and Bacteriological Profiles of Patients with Typhoid Fever Treated during 1975-1998 in the Tokyo Metropolitan Komagome Hospital
- Rapid, sensitive and specific diagnosis of Bordetella pertussis using the polymerase chain reaction
- Enzyme Linked Immunosorbent Assay of Rubella Antibody
- Evaluation of polymerization-dependent changes in color and translucency of resin composites using two formulae
- Specific Deposition of Passively Transferred Monoclonal Antibodies against Herpes Simplex Virus Type 1 in Rat Brain Infected with the Virus
- A rapid, simple and sensitive flow cytometric system for detection of Plasmodium falciparum
- A Message to International Readers
- Reports on Cases of Neurological Illnesses Occurring after Administration of Acellular Pertussis Vaccines in Japan(B. Vaccine Schedules: Their Pelationship to Current Epidemiology)(II. The Eradication of Pertussis: Current Unsolved Epidemiologic, Clinical
- Experiences with Acellular Pertussis Vaccine in Japan and Epidemiology of Pertussis
- Epidemiology of Pertussis in Japan(I. Current Situation of Acellular Pertussis Vaccines)(Clinical Aspects of Acellular Pertussis Vaccines)
- Glaucomatous eye macular ganglion cell complex thickness and its relation to temporal circumpapillary retinal nerve fiber layer thickness
- Respiratory failure caused by dual infection with Bordetella pertussis and respiratory syncytial virus
- Serum adipokine profiles in Kawasaki disease
- Syntheses and properties of [1,1'-bis(.ALPHA.-aminoisobutyric acid)]gramicidin S and [1-.ALPHA.-aminoisobutyric acid]semigramicidin S.
- Field Trial with a Further Attenuated Live Measles Virus Vaccine
- Complement Requirement of the Neutralizing Antibody Appearing After Immunization with Smallpox Vaccine